Protagonist Therapeutics, Inc Increase (Decrease) in Accounts Receivable, Related Parties
Protagonist Therapeutics, Inc (PTGX) reported Increase (Decrease) in Accounts Receivable, Related Parties of $155.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-21.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties · last filed 2025-02-21
- Protagonist Therapeutics, Inc increase (decrease) in accounts receivable, related parties for the quarter ending 2024-12-31 was $165.00M, a 1550.00% increase year-over-year.
- Protagonist Therapeutics, Inc increase (decrease) in accounts receivable, related parties for the quarter ending 2024-09-30 was -$43.00K.
- Protagonist Therapeutics, Inc increase (decrease) in accounts receivable, related parties for the quarter ending 2024-06-30 was -$300.00M.
- Protagonist Therapeutics, Inc increase (decrease) in accounts receivable, related parties for the quarter ending 2024-03-31 was $290.04M, a 707321.95% increase year-over-year.
- Protagonist Therapeutics, Inc increase (decrease) in accounts receivable, related parties for fiscal 2024 was $155.00M, a 1451.55% increase from fiscal 2023.
- Protagonist Therapeutics, Inc increase (decrease) in accounts receivable, related parties for fiscal 2023 was $9.99M.
- Protagonist Therapeutics, Inc increase (decrease) in accounts receivable, related parties for fiscal 2022 was -$1.56M.
- Protagonist Therapeutics, Inc increase (decrease) in accounts receivable, related parties for fiscal 2021 was -$860.00K.
| Period end | Increase (Decrease) in Accounts Receivable, Related Parties 3 month | Increase (Decrease) in Accounts Receivable, Related Parties 6 month | Increase (Decrease) in Accounts Receivable, Related Parties 9 month | Increase (Decrease) in Accounts Receivable, Related Parties 12 month |
|---|---|---|---|---|
| 2024-12-31 | $165.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $164.96M derived: sum of 2 quarters · filed 2025-02-21 | -$135.04M derived: sum of 3 quarters · filed 2025-02-21 | $155.00M 10-K · filed 2025-02-21 |
| 2024-09-30 | -$43.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$300.04M derived: sum of 2 quarters · filed 2024-11-07 | -$10.00M 10-Q · filed 2024-11-07 | $0.00 derived: sum of 4 quarters · filed 2025-02-21 |
| 2024-06-30 | -$300.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$9.96M 10-Q · filed 2024-08-06 | $43.00K derived: sum of 3 quarters · filed 2025-02-21 | $4.00K derived: sum of 4 quarters · filed 2025-02-21 |
| 2024-03-31 | $290.04M 10-Q · filed 2024-05-07 | $300.04M derived: sum of 2 quarters · filed 2025-02-21 | $300.00M derived: sum of 3 quarters · filed 2025-02-21 | $299.99M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $9.96M derived: sum of 2 quarters · filed 2025-02-21 | $9.95M derived: sum of 3 quarters · filed 2025-02-21 | $9.99M 10-K · filed 2025-02-21 |
| 2023-09-30 | -$39.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$51.00K derived: sum of 2 quarters · filed 2024-11-07 | -$10.00K 10-Q · filed 2024-11-07 | -$125.00K derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | -$12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $29.00K 10-Q · filed 2024-08-06 | -$86.00K derived: sum of 3 quarters · filed 2025-02-21 | -$4.00K derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $41.00K 10-Q · filed 2024-05-07 | -$74.00K derived: sum of 2 quarters · filed 2025-02-21 | $8.00K derived: sum of 3 quarters · filed 2025-02-21 | -$25.10M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | -$115.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$33.00K derived: sum of 2 quarters · filed 2025-02-21 | -$25.14M derived: sum of 3 quarters · filed 2025-02-21 | -$1.56M 10-K · filed 2025-02-21 |
| 2022-09-30 | $82.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$25.02M derived: sum of 2 quarters · filed 2023-11-02 | -$1.44M 10-Q · filed 2023-11-02 | -$2.51M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$25.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$1.52M 10-Q · filed 2023-08-03 | -$2.60M derived: sum of 3 quarters · filed 2024-02-27 | -$7.03M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $23.58M 10-Q · filed 2023-05-04 | $22.51M derived: sum of 2 quarters · filed 2024-02-27 | $18.07M derived: sum of 3 quarters · filed 2024-02-27 | $21.15M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$5.51M derived: sum of 2 quarters · filed 2024-02-27 | -$2.43M derived: sum of 3 quarters · filed 2024-02-27 | -$860.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | -$4.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$1.36M derived: sum of 2 quarters · filed 2022-11-08 | $212.00K 10-Q · filed 2022-11-08 | -$151.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $3.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $4.65M 10-Q · filed 2022-08-04 | $4.29M derived: sum of 3 quarters · filed 2023-03-15 | $4.08M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $1.57M 10-Q · filed 2022-05-05 | $1.21M derived: sum of 2 quarters · filed 2023-03-15 | $999.00K derived: sum of 3 quarters · filed 2023-03-15 | $402.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | -$363.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$571.00K derived: sum of 2 quarters · filed 2023-03-15 | -$1.17M derived: sum of 3 quarters · filed 2023-03-15 | -$4.33M 10-K · filed 2023-03-15 |
| 2020-09-30 | -$208.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$805.00K derived: sum of 2 quarters · filed 2021-11-03 | -$3.97M 10-Q · filed 2021-11-03 | $844.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$597.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$3.76M 10-Q · filed 2021-08-04 | $1.05M derived: sum of 3 quarters · filed 2022-02-28 | -$1.89M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$3.16M 10-Q · filed 2021-05-04 | $1.65M derived: sum of 2 quarters · filed 2022-02-28 | -$1.29M derived: sum of 3 quarters · filed 2022-02-28 | -$1.47M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $4.81M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.87M derived: sum of 2 quarters · filed 2022-02-28 | $1.69M derived: sum of 3 quarters · filed 2022-02-28 | $2.17M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$2.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$3.12M derived: sum of 2 quarters · filed 2020-11-04 | -$2.64M 10-Q · filed 2020-11-04 | -$2.64M derived: sum of 4 quarters · filed 2021-03-10 |
| 2019-06-30 | -$172.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $302.00K 10-Q · filed 2020-08-06 | $303.00K derived: sum of 3 quarters · filed 2021-03-10 | -$895.00K derived: sum of 4 quarters · filed 2021-03-10 |
| 2019-03-31 | $474.00K 10-Q · filed 2020-05-07 | $475.00K derived: sum of 2 quarters · filed 2021-03-10 | -$723.00K derived: sum of 3 quarters · filed 2021-03-10 | $2.34M derived: sum of 4 quarters · filed 2021-03-10 |
| 2018-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | -$1.20M derived: sum of 2 quarters · filed 2021-03-10 | $1.86M derived: sum of 3 quarters · filed 2021-03-10 | $2.77M 10-K · filed 2021-03-10 |
| 2018-09-30 | -$1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $1.86M derived: sum of 2 quarters · filed 2019-11-06 | $2.77M 10-Q · filed 2019-11-06 | $4.07M derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-06-30 | $3.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $3.97M 10-Q · filed 2019-08-07 | $5.26M derived: sum of 3 quarters · filed 2020-03-10 | |
| 2018-03-31 | $906.00K 10-Q · filed 2019-05-08 | $2.20M derived: sum of 2 quarters · filed 2020-03-10 | ||
| 2017-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $1.82M 10-K · filed 2020-03-10 | ||
| 2017-09-30 | $520.00K 10-Q · filed 2018-11-06 | |||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |